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Chlornitrofen [2,4,6-trichlorophenyl-4´-
nitrophenyl ether (CNP); Figure 1] was
widely used in large quantities as a herbicide
to control various weeds in rice fields in
Japan during the period 1965–1994. This
herbicide was produced and used mostly in
Japan. The amount of the active ingredient
of CNP used in Japan was estimated to be
82,359 tons (Masunaga et al. 1998). Several
studies reported unusually high levels of
CNP residue in freshwater fish and shellfish
during the application period (Ohyama et al.
1986; Watanabe et al. 1981, 1983; Yamagishi
and Akiyama 1981). CNP is also known to
convert to its corresponding amino derivative
[2,4,6-trichlorophenyl-4´-aminophenyl ether
(CNP-amino); Figure 1] by reduction of the
CNP nitro group in the soil of paddy fields
(Kuwatsuka 1977; Shimotori and Kuwatsuka
1978). There have also been reports of the
isolation of CNP and CNP-amino from tap
water and shellfish (Adachi 1994; Suzuki
et al. 1983). Yamamoto et al. (1987) reported
that the standardized mortality ratios of bil-
iary tract cancer were high in Niigata prefec-
ture, especially in the Niigata plain, and that
this phenomenon could be related to the use
of CNP. Thus, the use of CNP is thought to
cause water pollution in rice-growing areas
in Japan and lead to a high accumulation of
CNP and CNP-amino in fish and shellfish
in lakes and seas surrounding areas of rice
cultivation.
Recently, it has been well documented
that several chemicals from agricultural,
industrial, and household sources possess
endocrine-disrupting properties that are a
potential threat to human and wildlife repro-
duction (Colborn 1995; Colborn et al. 1993;
Jensen et al. 1995). The mechanism of action
of these effects is considered to consist mainly
of agonistic or antagonistic effects on hor-
mone receptors. For example, it has already
been reported that several pesticides or their
metabolites such as vinclozolin, 1,1-dichloro-
2,2-bis(p-chlorophenyl)ethylene (p,p´-DDE),
fenitrothion, and procymidone are androgen
receptor (AR) antagonists (Kelce et al. 1995;
Ostby et al. 1999; Tamura et al. 2001; Wong
et al. 1995) and that pesticides such as
1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane
(p,p´-DDT) and methoxychlor are estrogen
receptor (ER) agonists (Chen et al. 1997;
Shelby et al. 1996). Moreover, it has been
reported that some of the environmental
estrogens such as 1,1,1-trichloro-2-(p-chloro-
phenyl)-2-(o-chlorophenyl)ethane (o,p´-DDT),
bisphenol A, and butyl benzyl phthalate also
have antiandrogenic activitiy (Sohoni and
Sumpter 1998). Although CNP and CNP-
amino are thought to form methemoglobin,
induce hepatic drug-metabolizing enzymes, and
display mutagenicity (Hanioka et al. 1995;
Miyauchi et al. 1981, 1983; Oguri et al. 1995),
the endocrine-disrupting effects of CNP or
CNP-amino have not yet been described.
The reporter gene assay has been widely
used as an in vitro method for clarifying the
ligand–receptor interaction by receptor ago-
nists and antagonists. To detect the (anti)hor-
monal activities of environmental chemicals,
some investigators have performed reporter
gene assays using yeast cells, HepG2 cells,
Hela cells, and so forth (Gaido et al. 1997;
Maness et al. 1998; Nishikawa et al. 1999;
Saito et al. 2000). However, these assays all
encounter problems in the membrane trans-
port of chemicals, sensitivity, or complicated
procedures. In this study, we established two
transient reporter gene assays for detecting
transcriptional activities via AR and ER activ-
ities using transfection reagent FuGene6 and
Chinese hamster ovary (CHO) cells based on
the method of Vinggaard et al. (1999). The
method is rapid, sensitive, and reproducible.
Using this assay, we investigated the effects of
CNP and CNP-amino on androgenic and
estrogenic activities. In addition, the binding
afﬁnities of CNP and CNP-amino to human
androgen receptor (hAR) and human estro-
gen receptor-α (hERα) were also investigated
using a receptor competitive-binding assay
(Satoh et al. 2000, 2001). Here we provide
the ﬁrst evidence that CNP and CNP-amino
might be endocrine-disrupting chemicals
with both antiandrogenic and estrogenic
activities that act via hormone receptors.
Materials and Methods
Chemicals and cell culture materials. 5α-
Dihydrotestosterone (DHT, 95% pure),
testosterone (> 97% pure), 17β-estradiol (E2,
> 97% pure), estrone (98% pure), proges-
terone (98% pure), cortisol (> 97% pure),
and dimethylsulfoxide (DMSO), used for
conﬁrming the speciﬁcity of the assay system,
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Chlornitrofen (CNP) was widely used in large quantities as a herbicide in rice paddy ﬁelds in Japan
during 1965–1994. Recently, there has been concern that chemicals in the environment may disrupt
the endocrine function of wildlife and humans, but little is known about the effect of CNP on
endocrine function. We have developed reporter gene assays for human androgen receptor (hAR)
and human estrogen receptor-α (hERα) using Chinese hamster ovary cells. Using this assay method,
we measured CNP and its amino derivative (CNP-amino) for hAR and hERα agonist/antagonist
activities, comparing them with several well-known AR antagonists or ER agonists. We found that
CNP and CNP-amino have potent antiandrogenic activities as well as estrogenic activities. The
order of their antiandrogenic activity was CNP > vinclozolin > o,p´-DDT = p,p´-DDE > CNP-
amino, and the order of their estrogenic activity was o,p´-DDT > CNP-amino > p,p´-DDT > CNP.
We investigated the binding ability of CNP and CNP-amino to hAR and hERα using a receptor
competitive-binding assay. The order of their binding potencies to hAR was CNP > o,p´-DDT =
p,p´-DDE = CNP-amino > vinclozolin, and that of their binding potencies to hERα was o,p´-DDT
> CNP-amino > p,p´-DDT = CNP. These results suggest that both CNP and CNP-amino may act
as endocrine disruptors via AR and ERα in humans and other animals. Our reporter gene assays are
highly sensitive and speciﬁc and are suitable for screening AR and ERα agonist/antagonists among
numerous environmental chemicals. Key words: antiandrogenic activity, Chinese hamster ovary
cells, chlornitrofen, chlornitrofen-amino, estrogenic activity, human androgen receptor, human
estrogen receptor α, reporter gene assay. Environ Health Perspect 111:497–502 (2003).
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Figure 1. Chemical structures of CNP and CNP-amino.
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were purchased from Wako Pure Chemical
Industries (Osaka, Japan). CNP (99% pure),
CNP-amino (> 98.5% pure), vinclozolin
(> 99% pure), p,p´-DDT (> 99% pure), o,p´-
DDT (> 99% pure), and tamoxifen citrate
(98% pure) were also obtained from Wako
Pure Chemical Industries. p,p´-DDE (99%
pure) was obtained from GL Sciences
(Tokyo, Japan). Test compounds were solubi-
lized in DMSO. The luciferase reporter vec-
tors pGL3-Basic (containing the firefly
luciferase gene) and pRL-SV40 (containing
the Renilla luciferase gene, transfections and
toxicity control), and the dual-luciferase
reporter assay system were purchased from
Promega (Madison, WI, USA). The transfec-
tion reagent FuGene6 was obtained from
Roche Diagnostics Corp. (Indianapolis, IN,
USA). Dulbecco’s modiﬁed Eagle’s minimum
essential medium (DMEM/F-12) and peni-
cillin–streptomycin solution (antibiotics) were
obtained from GIBCO-BRL (Rockville, MD,
USA). Fetal bovine serum (FBS) and char-
coal–dextran-treated FBS (CD-FBS) were
obtained from Hyclone (Logan, UT, USA).
CHO-K1 cells obtained from the American
Type Culture Collection were grown at 37°C
in DMEM/F-12 supplemented with 10%
FBS and antibiotics.
Construction of plasmids. AR cDNA
and ERα cDNA were cloned by reverse
transcriptase–polymerase chain reaction from
human prostate and human placenta RNA
(Clontech, Palo Alto, CA, USA), respectively.
The sequences of the cloned hAR and hERα
cDNA were verified and were inserted into
mammalian expression vector pZeoSV2(-)
and pcDNA3.1Zeo(-) (Invitrogen, San
Diego, CA, USA), creating pZeoSV2AR and
pcDNAERα, respectively.
We constructed a reporter plasmid for the
AR-mediated transcriptional assay (AR assay)
based on the mammalian inducible expression
vector pIND/Hygro (Invitrogen), which orig-
inally contains ecdysone/glucocorticoid-
responsive element (ecdysone/GRE). Brieﬂy,
the luciferase gene (digested HindIII and
XbaI) from pGL-3 basic was cloned into
pIND/Hygro, creating pIND-LUC. To
remove the ecydsone/GRE and create a new
multicloning site (MCS), pIND/Hygro was
digested with smaI. The digested fragment
(about 1,500 bp of smaI-smaI) contains a
minimal heat shock (hs) promoter without
ecydsone/GRE. Then, the oligonucleotides
5´-GATCTATCGATTCTAGAGGATC-
CTCGAGATATCCC-3´ and 5´-GGGAT-
ATCTCGAGGATCCTCTAGAATCGATG
A-3´ (containing BglII, ClaI, XbaI, BamHI,
XhoI, EcoRV) were ligated to this smaI-smaI
fragment from pIND/Hygro and then
digested with Bgl II and HindIII (about 300
bp, contains MCS and hs). And this small
fragment was inserted into the pIND-LUC
(digested with BglII and HindIII), creating
pIND-MCS-LUC. To introduce the andro-
gen responsive element (ARE) into the newly
created MCS, kinated oligonucleotides
5´-gatccatcatAGTACGtgaTGTTCTcaagaa-
3´and 5´-gatcttcttgAGAACAtcaCGTACT
atgatg-3´(flanking the BglII site) containing
ARE of the C3 gene of prostatic binding pro-
tein (Karvonen et al. 1997) were ligated and
then inserted into the BglII site of the pIND-
MCS-LUC, creating pINDARE (Figure 2A).
For the ERα-mediated transcriptional
assay (ERα assay), we constructed a reporter
plasmid pGL3-tkERE based on the pGL3
basic vector. A plasmid pRL-TK (Promega)
was digested with AvaII, followed by blunt-
ended treatment with Klenow fragment, and
then digested with HindIII. The digested
small fragment (about 70 bp ) from pRL-TK,
containing a deletion tk promoter, was cloned
into the blunt-ended BglII/HindIII site of
the pGL3 basic vector, creating pGL3-tk.
This vector has the minimal tk (–40 to +31)
promoter and carries only the TATA box of
the regulatory element. Then the kinated
strands of the oligonucleotides containing a
perfectly palindromic estrogen-responsive ele-
ment (ERE, AGGTCA cag TGACCT) from
the Xenopus vitellogenin gene (Klein-Hitpass
et al. 1986) were cloned into the kpnI site of
pGL3-tk, creating pGL3-tkERE (Figure 2B).
Sequencing veriﬁed that the pIND-ARE and
the pGL3-tkERE carried four tandem repeats
of ARE or ERE upstream of their promoter.
Reporter gene assays for hAR and hERα.
The host CHO-K1 cells were plated in 96-well
microtiter plates (Nalge, Nunc, Denmark) at
a density of 8,400 cells per well in phenol red-
free DMEM/F-12 containing 5% CD-FBS
(complete medium) 1 day before transfec-
tions. For detection of hAR activity, we trans-
fected cells with 2.5 ng pZeoSV2AR, 62.5 ng
pIND-ARE, and 5.0 ng pRL-SV40 per well
using the transfection reagent FuGene6. For
detection of hERα activity, we transfected
cells with 6.25 ng pcDNAERα, 62.5 ng
pGL3-tkERE, and 5.0 ng pRL-SV40 per
well. After a 3-hr transfection period, cells
were dosed with various concentrations of test
compounds or with 0.1% DMSO (vehicle
control) in complete medium. For measure-
ment of hAR and hERα antagonist activity,
we added 10–10M of DHT and 10–11 M of E2
to the cell cultures, respectively. After an
incubation period of 24 hr, cells were rinsed
with phosphate-buffered saline (pH 7.4) and
lysed with passive lysis buffer (50 µL/well)
provided with the dual-luciferase reporter
assay kit. The firefly luciferase activity was
measured before measuring Renilla luciferase
activity in one reaction tube with 5-µL
aliquots of cell lysates using the dual-luciferase
reporter assay system following the manufac-
turer’s instructions with a MiniLumat LB
9506 luminometer (Berthold, Germany). We
normalized the ﬁreﬂy luciferase activity to the
Renilla luciferase activity.
Competitive binding assay for AR and
ERα. We determined competitive binding of
CNP and CNP-amino against the binding of
the index hormone to AR by non-radioiso-
topic receptor binding assay using a ligand
screening system-androgen receptor kit
(Toyobo Co., Ltd., Osaka, Japan) as reported
by Satoh et al. (2001). The solutions of
human AR, unlabeled testosterone, and test
chemical (competitor) dissolved in DMSO
were reacted at 4°C for 1 hr. The liberated
testosterone was allowed to compete with the
antitestosterone antibody and peroxidase-
labeled testosterone at 4°C for 1 hr. After
plates were washed with a wash solution, the
substrate solution was added. We measured
the developed color at 450 nm on a
microplate-spectrophotometer (MPRA4i;
TOSOH Co., Ltd., Tokyo, Japan).
Competitive binding assay of CNP and
CNP-amino to ERα was performed using a
ligand screening system-estrogen receptor α
kit (Toyobo Co., Ltd., Osaka, Japan) as
reported by Satoh et al. (2000). Briefly, the
solutions of human ERα, unlabeled E2, and
test chemical dissolved in DMSO were
reacted at 4°C for 1 hr. The liberated E2 was Figure 2. Structures of luciferase reporter plasmids.
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allowed to compete with the anti-E2 antibody
and peroxidase-labeled E2 at 4°C for 1 hr. We
then assayed the developed color as described
above for AR binding assay.
We calculated the binding levels of the
chemicals to the respective receptors from the
decreases in absorbance rate. We used mibo-
lerone and diethylstilbestrol (DES) as positive
controls from the AR and ERα-binding
kits, respectively.
Data analysis. We evaluated the statistical
signiﬁcance of differences using the Student’s
t-test (two-tailed, equal variance) calculated
by software (Excel; Microsoft, Redmond,
WA, USA). The level of signiﬁcance was p <
0.05. Data are presented as the mean and,
where shown, the SD of at least three separate
experiments with duplicate wells.
Results
Sensitivity and speciﬁcity of the reporter assays
for hAR and hERα. We established two tran-
sient reporter gene assays for detecting tran-
scriptional activities via hAR and hERα using
transfection reagent FuGene6 and CHO cells.
To confirm the sensitivity and specificity of
our reporter gene assays, we tested various
endogenous steroids for hAR- and hERα-
mediated transcriptional activities, respectively.
Figure 3A shows the results for androgenic
activity. The androgenic activity of DHT was
observed in a dose-dependent manner at con-
centrations above 10–11M, and the maximum
induction was 16-fold that of the solvent con-
trol. The androgenic activity of testosterone
was observed at concentrations above 10–10 M,
and its transcriptional activity was approxi-
mately 1/10 that of DHT. Cortisol was also
able to stimulate luciferase synthesis, but the
activity was about 1/1,000 that of DHT. E2,
estrone, and progesterone showed only low
activity at the concentrations tested.
The results for estrogenic activity are
shown in Figure 3B. E2 activity became
detectable at the concentrations of more than
10–12 M, and the maximum induction was
9-fold that of the solvent control. The E2
metabolite, estrone, was as effective as E2 at
inducing luciferase activity. DHT showed
approximately 1/2,000 the intensity of E2 and
estrone. Testosterone and cortisol were also
tested and found positive by this assay at high
concentrations. Progesterone was inactive at
the concentration tested.
Effects of CNP and CNP-amino on the
hAR- and hERa-mediated reporter gene
assays. To investigate whether CNP and
CNP-amino have endocrine-disrupting
effects, we determined their androgenic and
estrogenic activities using the two assay sys-
tems described above. Figure 4A shows the
hAR-mediated transcriptional activities of
CNP, CNP-amino, vinclozolin, p,p´-DDE
and o,p´-DDT at a concentration of 10–5 M
in the absence or presence of 10–10 M DHT.
CNP was weakly androgenic, but CNP-
amino, as well as vinclozolin, p,p´-DDE, and
o,p´-DDT displayed no androgenicity
(Figure 4A). CNP and CNP-amino, how-
ever, inhibited the hAR-mediated transcrip-
tional activity by DHT, as did the AR
antagonists vinclozolin, p,p´-DDE, and o,p´-
DDT (Figure 4A). 
The dose-responsive inhibitory effects of
CNP and CNP-amino on DHT-induced
androgenic response are depicted in Figure
4B. CNP showed an antiandrogenic effect in a
dose-dependent manner at concentrations
from 10–8 to 10–6 M, but the inhibition curve
of CNP turned upward at the concentrations
> 10–6 M. CNP-amino showed an antiandro-
genic effect at concentrations of 10–7 – 10–5M.
These effects of CNP and CNP amino were
detectable without changes of Renilla luciferase
activity in cells (data not shown), indicating
that the present experimental condition did
not affect the cellular viability. When the
antiandrogenic potencies of each compound
were expressed as the concentration exhibiting
50% inhibition of the androgenic activity of
10–10 M DHT (IC50), the antiandrogenic
potencies of CNP (IC50 = 1.7 × 10–7 M) were
approximately 3.5-, 14-, and 10-fold higher
than those of vinclozolin (IC50 = 5.8 × 10–7
M), p,p´-DDE (IC50 = 2.4 × 10–6 M), o,p´-
DDT (IC50 = 1.6 × 10–6 M), respectively. The
antiandrogen potency of CNP-amino (IC50 =
2.5 × 10–6 M) was similar to those of p,p´-
DDE and o,p´-DDT, and more than 1/10 the
intensity of CNP.
Figure 5A shows the hERα-mediated
transcriptional activities induced by CNP,
CNP-amino, p,p´-DDT, and o,p´-DDT at a
concentration of 10–5 M and by therapeutic
antiestrogen, tamoxifen, at concentrations of
10–8 and 10–7 M in the absence or presence of
10–11 M E2. CNP and CNP-amino exhibited
potent estrogenic activity, as did p,p´-DDT
Figure 3. Dose response of various steroids on the human AR and human ERα reporter gene assays. CHO
cells were transiently transfected with expression plasmids for human AR (A) or ERα (B) plus relative
receptor responsive firefly luciferase reporter plasmids and a constitutively active Renilla luciferase
expression plasmid (transfection and toxicity control). Cells were treated with increasing concentrations
of various steroids to detect agonist activity. Fireﬂy luciferase activity was normalized to Renilla luciferase
activity. Values represent the means ± SD of three independent experiments and are presented as mean
fold-induction over the vehicle control.
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Figure 4. Effects of CNP and CNP-amino on human AR activity. (A) CHO cells, transiently cotransfected with
pZeoSV2AR, pIND-ARE and pRL-SV40, were incubated with the vehicle control (0.1% DMSO) or 10–5 M of CNP, CNP-
amino, vinclozolin, p,p´-DDE, or o,p´-DDT in the absence or presence of 10–10 M DHT. Values represent the means ±
SD of three independent experiments and are presented as mean fold-induction over the vehicle control. (B) Cells
were incubated with various concentrations of CNP, CNP-amino, vinclozolin, p,p´-DDE, or o,p´-DDT in the presence of
10–10 M DHT. Values represent the means ± SD of three independent experiments and are presented as percentage
induction, with 100% activity deﬁned as the activity achieved with 10–10 M DHT.
*Signiﬁcant difference at p < 0.05 by Student’s t-test.
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and o,p´-DDT, the ER agonists, at the
concentration of 10–5 M, but tamoxifen was
inactive at 10–8 and 10–7 M (Figure 5A). In
the presence of 10–11 M E2, CNP, CNP-
amino, p,p´-DDT, and o,p´-DDT did not
show any significant differences from the
vehicles, whereas tamoxifen inhibited the
estrogenic activity of E2 in a dose-dependent
manner at 10–8 and 10–7 M (Figure 5A). The
dose–response curves for the estrogenic activi-
ties of CNP and CNP-amino are shown
together with those of p,p´-DDT, o,p´-DDT,
and tamoxifen in Figure 5B. When the estro-
genic potencies of each compound were
expressed as the concentration showing 50%
the estrogenic activity of 10–10 M E2 (EC50),
the EC50 values of CNP, CNP-amino, p,p´-
DDT, and o,p´-DDT were 1.0 × 10–5 M, 9.3
× 10–7 M, 3.8 × 10–6 M, and 4.6 × 10–7 M,
respectively. The order of the estrogenic poten-
cies of the five compounds was as follows:
o,p´-DDT > CNP-amino > p,p´-DDT > CNP.
Competitive inhibition of the binding of
testosterone and estradiol to hAR and hERα
by CNP and CNP-amino. Figure 6A shows
the competition curves depicting the effects of
various doses of CNP, CNP-amino, vinclo-
zolin, p,p´-DDE, o,p´-DDT, and mibolerone,
a synthetic anabolic testosterone, on the bind-
ing of testosterone to hAR. CNP and CNP-
amino inhibited the binding of testosterone to
hAR in a dose-dependent manner, as did p,p´-
DDE, o,p´-DDT, and mibolerone, and com-
plete inhibition was achieved by CNP and
CNP-amino at concentrations > 10–5 M and
10–4 M, respectively. Vinclozolin, in contrast,
showed very low binding affinity for hAR.
The IC50 (concentration of test compound
exhibiting 50% inhibition against the binding
of testosterone to hAR) values were obtained
from the curves, and the relative binding
afﬁnities for hAR (RBA-A) were expressed as
the ratio of the IC50 of mibolerone to that of
each compound (Table 1). The IC50 values of
CNP and CNP-amino were 2.2 × 10–7 M and
5.7 × 10–6 M, respectively. The RBA-A of
CNP and CNP-amino were 8.64 and 0.33
compared to 100 for mibolerone.
Figure 6B shows the competition curves
showing the effects of CNP, CNP-amino,
p,p´-DDT, o,p´-DDT, and DES, a synthetic
estrogenic drug, on the binding of E2 to
hERα. The effect of CNP on the binding of
E2 to hERα was very low, similar to that of
p,p´-DDT. However, CNP-amino and o,p´-
DDT showed inhibition ranging from 3 ×
10–6 to 10-4 M and 3 × 10–7 to 10–4 M,
respectively. The IC50 (concentration of test
compound exhibiting 50% inhibition against
the binding of E2 to ERα) values were
obtained from the curves, and the relative
binding affinities for ERα (RBA-E) were
expressed as the ratio of the IC50 of E2 to that
of each compound (Table 1). The IC50 of
CNP and CNP-amino were > 1 × 10–3 M
and 2.4 × 10–5 M, respectively. The RBA-E
of CNP and CNP-amino were < 0.0009 and
0.036 compared to 100 for DES.
Discussion
In this study, we ﬁrst developed the hAR- and
hERα-mediated reporter gene assays using
CHO-K1 cells to examine the effects of CNP
and CNP-amino on sex hormone receptors.
Our AR and ER assay systems showed high
sensitivity to androgenic and estrogenic com-
pounds, respectively, when compared with
other assay systems using yeast cells and
Table 1. Competitive binding abilities of CNP and CNP-amino for hAR and hERα.
hAR hERα
Compound IC50 (M)a RBA-Ab IC50 (M)c RBA-Ed
Mibolerone 1.9 × 10–8 100 ND ND
DES ND ND 8.6 × 10–9 100
CNP 2.2 × 10–7 8.64 > 10–3 < 0.0009
CNP-amino 5.7 × 10–6 0.33 2.4 × 10–5 0.036
Vinclozolin 1.5 × 10–4 0.013 ND ND
p,p´-DDT ND ND > 10–3 < 0.0009
p,p´-DDE 5.4 × 10–6 0.35 ND ND
o,p´-DDT 5.6 × 10–6 0.34 9.1 × 10–7 0.95
ND, no data. 
aIC50, the concentration of test compound exhibiting 50% inhibition against the binding of teststerone to hAR. bRBA-A (relative
binding afﬁnity for hAR) was expressed as a ratio of IC50 of mibolerone to that of test compounds. cIC50, the concentration of
test compound exhibiting 50% inhibition against the binding of E2 to hERα. dRBA-E (relative binding afﬁnity for hERα) was
expressed as a ratio of IC50 of DES to that of test compounds. RBA values for mibolerone and DES were arbitrarily set at 100. 
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Figure 5. Effects of CNP and CNP-amino on human ERα activity. (A) CHO cells, transiently cotransfected
with pcDNAERα, pGL3-tkERE and pRL-SV40, were incubated with the vehicle control (0.1% DMSO) or 10–5
M of CNP, CNP-amino, p,p´-DDT, o,p´-DDT, or 10–7 M of tamoxifen in the absence or presence of 10–11 M
E2. Values represent the means ± SD of three independent experiments and are presented as mean fold-
induction over the vehicle control. (B) Cells were incubated with various concentrations of CNP, CNP-
amino, p,p´-DDT, or o,p´-DDT. Values represent the means ± SD of three independent experiments and are
presented as percentage induction, with 100% activity deﬁned as the activity achieved with 10–10 M E2.
*Signiﬁcant difference at p < 0.05 by Student’s t-test.
Figure 6. Competitive binding of CNP and CNP-amino to human AR and human ERα. Competitive binding
assay was carried out using a ligand screening system-androgen receptor kit (A) and an ERα kit (B).
Percentage of testosterone bound to hAR was calculated as ([optical density in the presence of competi-
tor – optical density in the presence of 3 × 10–7 M mibolerone]/[optical density in the absence of competi-
tor – optical density in the presence of 3 × 10–7 M mibolerone]) × 100. Percentage of E2 bound to hERα was
calculated as ([optical density in the presence of competitor – optical density in the presence of 3 × 10–7 M
DES]/[optical density in the absence of competitor – optical density in the presence of 3 × 10–7 M DES]) ×
100. Each point is the mean ± SD of three independent experiments with duplicate wells.
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HepG2 cells (Gaido et al. 1997; Maness et al.
1998; Nishikawa et al. 1999). This is thought
to be the result of the high transfection effi-
ciency of the FuGene transfection reagent for
CHO cells, as reported by Vinggaard et al.
(1999). In addition, our assay systems were
highly specific to androgenic and estrogenic
compounds, similar to the results obtained by
Gaido et al. (1997) with yeast cells. These
results suggest that both the hAR and hERα
assays described in the present study are supe-
rior to other reporter gene assays in terms of
rapidity, sensitivity, and reproducibility and
are useful in identifying endocrine disruptors
via AR and ERα from a large number
of chemicals.
Using our assay systems, we examined the
effects of CNP and CNP-amino on hAR
and hERα activities. In the hAR assay, both
CNP and CNP-amino were found to have a
dose-dependent, suppressive effect on the
DHT-induced transcriptional activity. It is
noteworthy that the antiandrogenic potency of
CNP was higher than that of well-known AR
antagonists such as vinclozolin, p,p´-DDE, and
o,p´-DDT. Moreover, CNP-amino also
showed an antiandrogenic activity almost equal
to those of the AR antagonists, indicating not
only that the parent compound CNP but also
its principal metabolite possess serious antian-
drogenic activities. What is intriguing was
ﬁnding that CNP also displayed weak AR ago-
nistic activity at high concentrations, while
CNP-amino did not (Figure 4B). These
diverse effects of CNP are similar to those of
the M2 (3´,5´-dichloro-2-hydroxy-2-methyl-
but-3-enanilide), one of the two primary
metabolites of vinclozolin, and hydroxyflu-
tamide (an active metabolite of flutamide),
both of which partially inhibit DHT activity
and display some agonistic activity at high con-
centrations (Kelce and Wilson 1997; Wong
et al. 1995). Thus, CNP is deﬁned as a partial
AR agonist/antagonist.
In the hERα assay, we found that CNP
and CNP-amino also possess estrogenic activ-
ity but not antiestrogenic activity. The estro-
genic activity of CNP was lower than the
activities of p,p´-DDT and o,p´-DDT, well-
known ER agonists; however, the estrogenic
activity of CNP-amino was about 4-fold
higher than that of p,p´-DDT. Nevertheless,
the estrogenic potencies of CNP and CNP-
amino were about 107- and 105-fold less
potent than that of the endogenous estrogen
E2. Nishikawa et al. (2000) examined the
estrogenic activities of 517 different kinds of
chemicals by a yeast two-hybrid assay and
judged CNP to be negative for estrogenic
activity at 10–5 M. This again suggests that
our hERα assay is more sensitive than the
yeast two-hybrid assay.
Using the competitive receptor-binding
assays, we identified that the antiandrogenic
and estrogenic activities of CNP and CNP-
amino measured by our AR and ER assay sys-
tems were mediated by way of the binding of
CNP and CNP amino to AR and ERα. The
binding abilities of CNP and CNP-amino, as
well as p,p´-DDE and o,p´-DDT, for hAR
were consistent with the antiandrogen activity
deﬁned in the reporter gene assay. In contrast,
vinclozolin, which showed potent antiandro-
genic activity in the hAR assay, showed poor
binding ability to hAR. Kelce et al. (1994)
reported that metabolites of vinclozolin
exhibited a potent binding ability to AR,
whereas the parent compound showed little
activity. In this context, it is likely that CHO-
K1 cells possess at least some biotransforma-
tion capacity, producing metabolites of
vinclozolin, as Vinggaard et al. (1999)
pointed out. The binding ability of CNP-
amino and o,p´-DDT for hERα well reﬂected
the hERα-transcriptional activation, whereas
that of CNP and p,p´-DDT for hERα was
somewhat low and did not correlate well with
the hERα-transcriptional activation. The lat-
ter discrepancy may represent a difference in
sensitivity between the reporter gene assay
and receptor-binding assay.
In this study, we demonstrated for the ﬁrst
time that CNP and CNP-amino possess both
antiandrogenic and estrogenic activities similar
to o,p´-DDT. This in turn indicates that, in
terms of the environment, CNP and CNP-
amino should be considered serious endocrine-
disrupting agents similar to other well-known
AR antagonists or ER agonists. The present
study also demonstrates the effectiveness of our
reporter gene assays for detecting chemical
interactions with hAR and hERα and for dis-
cerning receptor agonists from antagonists. It
has been reported that many chemicals have
more than one type of activity, and, in particu-
lar, a single chemical can have pleiotropic
effects, being able to bind to both the andro-
gen and estrogen receptors (Gaido et al. 2000;
Satoh et al. 2001; Sohoni and Sumpter 1998).
At present, we are searching for similar effects
in yet undeﬁned chemicals using our reporter
gene assays.
There are a number of points of interest
in the chemical structures of CNP and CNP-
amino. The difference in chemical structure
between CNP and CNP-amino is that a nitro
group connected to the benzene ring in CNP
is replaced by an amino group. This indicates
that the difference between the nitro and
amino group in their structure regulates their
binding afﬁnities to hAR and hERα and that
the nitro group of CNP and the amino group
of CNP-amino may play important roles in
the transcriptional activity through the bind-
ing to the ligand-binding domain of hAR and
hERα, respectively. Such a phenomenon may
occur in other diphenylether herbicides such
as nitrofen, chlomethoxynil, and bifenox,
which have molecular structures similar to
that of CNP and are converted to correspond-
ing amino derivatives in the environment
(Kuwatsuka 1977). Furthermore, Tamura et
al. (2001) demonstrated that the organophos-
phate insecticide fenitrothion, which has a
nitro group connected to the benzene ring
similar to pharmaceutical antiandrogen flu-
tamide, possesses potent antiandrogenic activ-
ity in vitro and in vivo. The existence of nitro
benzene in the molecular structure may be an
important key in identifying antiandrogenic
compounds.
Because vinclozolin and p,p´-DDE, which
were used as positive control chemicals in this
study, are known to have in vivo antiandro-
genic activity (Gray et al. 1994; Kelce et al.
1995, 1997), further studies are required to
confirm the AR antagonist and ER agonist
effects of CNP and CNP-amino by in vivo
assays such as the Hershberger antiandrogen
assay (Kelce et al. 1997; Lambright et al. 2000)
and the uterotrophic assay (Odum et al. 1997).
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